Other manufacturing industries
Rege Nephro Co., Ltd.
Rege Nephro Co., Ltd.
Our core technology is the ability to generate a variety of kidney cells from iPS cells, and we are currently developing cell therapy for chronic kidney disease using iPS cell-derived renal progenitor cells, as well as therapeutics for autosomal dominant polycystic kidney disease, which was explored using iPS cell-derived disease models. In Japan, there are 340,000 patients undergoing dialysis treatment due to end-stage renal disease, and medical costs amount to 2 trillion yen annually. There is no fundamental treatment other than kidney transplantation. ADPKD is a genetic disease caused by a single gene mutation that has the highest number of patients and is also in high demand.
Area of Interest
Site-visit
SDGs we are working on
Registered Keyword
Area of Interest
- North America
- Europe
- West Asia
- South Asia
- Southeast Asia
- China
- East Asia (excluding China)
Site-visit
Not allowed
SDGs we are working on
3.Good health and well-being
9.Industry, innovation, infrastructure
Registered Keyword
Our core technology is the ability to generate a variety of kidney cells from iPS cells, and we are currently developing the following two major products, (1) cell therapy for chronic kidney disease using iPS cell-derived renal progenitor cells, (2) therapeutics for autosomal dominant polycystic kidney disease, which was explored using iPS cell-derived disease models.